APA (7th ed.) Citation

X, T., V, D., J, A., L, X., KB, C., CL, G., . . . AA, K. (2024). Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE). Clinical drug investigation, 44(4), 271. https://doi.org/10.1007/s40261-024-01354-2

Chicago Style (17th ed.) Citation

X, Tan, Divino V, Amamoo J, Xie L, Coyle KB, Gamble CL, Guevarra M, Paprocki Y, and King AA. "Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)." Clinical Drug Investigation 44, no. 4 (2024): 271. https://doi.org/10.1007/s40261-024-01354-2.

MLA (9th ed.) Citation

X, Tan, et al. "Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE)." Clinical Drug Investigation, vol. 44, no. 4, 2024, p. 271, https://doi.org/10.1007/s40261-024-01354-2.